Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: Management and results at long-term follow-up

Urologia Internationalis

Volumn 85, Issue 3, 2010, Pages 281-286

  Villavicencio, Humberto ^a   Rodriguez Faba, Oscar ^a,c   Palou, Joan ^a   Gausa, Luis ^a   Algaba, Ferran ^a   Marcuello, Eugenio ^b  

^a FUNDACIÓ PUIGVERT   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c NONE   (Spain)

Author keywords

Bladder preservation; Chemotherapy; Cystectomy; Transurethral resection

Indexed keywords

BCG VACCINE; CARBOPLATIN; METHOTREXATE; VINBLASTINE;

ADULT; AGE; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; SEX;

AGED; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MUSCLES; NEOPLASM INVASIVENESS; REMISSION INDUCTION; TIME FACTORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 78049472587     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316076     Document Type: Article

References (19)

1. Soloway MS, Lopez AE, Patel J, Lu Y: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 1994; 73: 1926-1931. (Pubitemid 24101973)
2. Maurer T, Maurer J, Retz M, et al: Influence of body mass index on operability, morbidity and disease outcome following radical cystectomy. Urol Int 2009; 82: 432-439.
3. Kuczyk M, Turkeri L, Hammerer P, Ravery V: Is there a role for bladder-preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 2003; 44: 57-64. (Pubitemid 36741376)
4. Shipley WU, Kaufman DS, Zehr KE, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-67. (Pubitemid 34722947)
5. Sternberg CN, Donat SM, Bellmunt J, et al: Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69(suppl 1A):69-72. (Pubitemid 46186484)
6. Angulo JC, Sánchez-Chapado M, Flores JI, Flores N: Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis of prognostic factors. J Urol 1996; 155: 1897-1902. (Pubitemid 26144080)
7. Baltaci S, Resorlu B, Yagci C, Turkolmez K, Gogus C, Beduk Y: Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int 2008; 81: 399-402.
8. Bellmunt J, Albanell J, Gallego OS, et al: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992; 70: 1974-1979.
9. Waxman J, Abel P, James N, et al: New combination chemotherapy programme for bladder cancer. Br J Urol 1989; 63: 68-71. (Pubitemid 19027420)
10. Petrioli R, Frediani B, Manganelli A, et al: Comparison between cisplatin-containing regimen and carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 344-351. (Pubitemid 26023354)
11. Culine E: Chemotherapy for advanced transitional cell carcinoma of the urothelium: Cisplatin or carboplatin? Eur Urol 2007; 54: 9-10. (Pubitemid 46803011)
12. Solsona E, Iborra I, Ricós JV, Monrós JL, Dumont R: Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Prospective study. J Urol 1992; 147: 1513-1515.
13. Herr HW: Transurethral resection of muscle- invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93. (Pubitemid 32063483)
14. Srougi M, Simon SD: Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy in bladder preservation in locally invasive bladder cancer: A 5-year follow-up. J Urol 1994; 151: 593. (Pubitemid 24054691)
15. Shipley WU, Kaufman DS, Hen NM, et al: An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur Urol 1998; 33(suppl):32.
16. Yencilek F, Onal B, Erozenci A, Talat Z, Ataus S: Intermediate-risk group in patients with transitional cell carcinoma of the bladder: Prediction of high-risk patients in this heterogeneous group. Urol Int 2009; 83: 295-299.
17. Solsona E, Climent MA, Iborra I, et al: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: Long-term followup of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:911-921.
18. Given RW, Parsons JT, McCarley D, Wajsman Z: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 1995; 46: 499. (Pubitemid 26100432)
19. Pieras E, Palou J, Salvador J, Rosales A, Marcuello E, Villavicencio H: Management and prognosis of transitional cell carcinoma. Superficial recurrence in muscle-invasive bladder cancer after preservation. Eur Urol 2003; 44: 222-225. (Pubitemid 36917007)